



(51) International Patent Classification:

A61K 38/16 (2006.01) A61K 38/48 (2006.01)
A61K 31/7028 (2006.01) A61P 27/02 (2006.01)

(21) International Application Number:

PCT/US2023/066620

(22) International Filing Date:

04 May 2023 (04.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/338,392 04 May 2022 (04.05.2022) US

(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: **BLOUSE, Grant E.**; 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080 (US). **LE MOAN, Natacha**; 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080 (US). **KNUDSEN, Tom**; 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080 (US).

(74) Agent: **ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPLEMENT FACTOR I DOSING REGIMENS FOR TREATING OCULAR DISEASES




FIG. 1

(57) Abstract: Provided herein are dosing regimens for the treatment of ocular conditions such as age-related macular degeneration (AMD). The regimens comprise administering to a subject in need thereof fusion constructs comprising a Complement Factor I (CFI) and a binding partner at specified doses and frequencies.

